REGENERON PHARMACEUTICALS (REGN) Fundamental Analysis & Valuation

NASDAQ:REGN • US75886F1075

Current stock price

744.44 USD
-7.13 (-0.95%)
At close:
751 USD
+6.56 (+0.88%)
Pre-Market:

This REGN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. REGN Profitability Analysis

1.1 Basic Checks

  • REGN had positive earnings in the past year.
  • REGN had a positive operating cash flow in the past year.
  • Each year in the past 5 years REGN has been profitable.
  • Each year in the past 5 years REGN had a positive operating cash flow.
REGN Yearly Net Income VS EBIT VS OCF VS FCFREGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

1.2 Ratios

  • REGN has a better Return On Assets (11.11%) than 93.59% of its industry peers.
  • REGN has a better Return On Equity (14.41%) than 93.20% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 9.60%, REGN belongs to the top of the industry, outperforming 93.40% of the companies in the same industry.
  • REGN had an Average Return On Invested Capital over the past 3 years of 11.30%. This is significantly below the industry average of 28.06%.
Industry RankSector Rank
ROA 11.11%
ROE 14.41%
ROIC 9.6%
ROA(3y)11.58%
ROA(5y)16.27%
ROE(3y)14.89%
ROE(5y)21.37%
ROIC(3y)11.3%
ROIC(5y)18.08%
REGN Yearly ROA, ROE, ROICREGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

1.3 Margins

  • REGN has a Profit Margin of 31.41%. This is amongst the best in the industry. REGN outperforms 94.95% of its industry peers.
  • In the last couple of years the Profit Margin of REGN has declined.
  • The Operating Margin of REGN (27.02%) is better than 94.76% of its industry peers.
  • REGN's Operating Margin has declined in the last couple of years.
  • REGN has a Gross Margin of 86.56%. This is amongst the best in the industry. REGN outperforms 87.77% of its industry peers.
  • REGN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 27.02%
PM (TTM) 31.41%
GM 86.56%
OM growth 3Y-14.45%
OM growth 5Y-8.44%
PM growth 3Y-4.13%
PM growth 5Y-5.35%
GM growth 3Y-1.04%
GM growth 5Y-0.06%
REGN Yearly Profit, Operating, Gross MarginsREGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. REGN Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so REGN is still creating some value.
  • REGN has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, REGN has less shares outstanding
  • REGN has a better debt/assets ratio than last year.
REGN Yearly Shares OutstandingREGN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
REGN Yearly Total Debt VS Total AssetsREGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.2 Solvency

  • An Altman-Z score of 7.39 indicates that REGN is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of REGN (7.39) is better than 76.70% of its industry peers.
  • REGN has a debt to FCF ratio of 0.72. This is a very positive value and a sign of high solvency as it would only need 0.72 years to pay back of all of its debts.
  • The Debt to FCF ratio of REGN (0.72) is better than 94.76% of its industry peers.
  • A Debt/Equity ratio of 0.09 indicates that REGN is not too dependend on debt financing.
  • REGN has a Debt to Equity ratio of 0.09. This is in the lower half of the industry: REGN underperforms 62.52% of its industry peers.
  • Even though the debt/equity ratio score it not favorable for REGN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 0.72
Altman-Z 7.39
ROIC/WACC1.03
WACC9.3%
REGN Yearly LT Debt VS Equity VS FCFREGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2.3 Liquidity

  • REGN has a Current Ratio of 4.13. This indicates that REGN is financially healthy and has no problem in meeting its short term obligations.
  • REGN's Current ratio of 4.13 is in line compared to the rest of the industry. REGN outperforms 48.93% of its industry peers.
  • A Quick Ratio of 3.56 indicates that REGN has no problem at all paying its short term obligations.
  • REGN has a Quick ratio (3.56) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.13
Quick Ratio 3.56
REGN Yearly Current Assets VS Current LiabilitesREGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. REGN Growth Analysis

3.1 Past

  • REGN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.76%.
  • The Earnings Per Share has been growing slightly by 6.99% on average over the past years.
  • The Revenue has been growing slightly by 0.99% in the past year.
  • The Revenue has been growing by 11.04% on average over the past years. This is quite good.
EPS 1Y (TTM)-2.76%
EPS 3Y1.53%
EPS 5Y6.99%
EPS Q2Q%-5.22%
Revenue 1Y (TTM)0.99%
Revenue growth 3Y5.62%
Revenue growth 5Y11.04%
Sales Q2Q%2.51%

3.2 Future

  • Based on estimates for the next years, REGN will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.77% on average per year.
  • The Revenue is expected to grow by 8.35% on average over the next years. This is quite good.
EPS Next Y5.64%
EPS Next 2Y11.49%
EPS Next 3Y12.23%
EPS Next 5Y10.77%
Revenue Next Year11.11%
Revenue Next 2Y10.62%
Revenue Next 3Y9.96%
Revenue Next 5Y8.35%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
REGN Yearly Revenue VS EstimatesREGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
REGN Yearly EPS VS EstimatesREGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20 40 60 80

More info and screens

Find the best growth stocksShow best growing peers

6

4. REGN Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 16.77, the valuation of REGN can be described as correct.
  • REGN's Price/Earnings ratio is rather cheap when compared to the industry. REGN is cheaper than 94.76% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.15. REGN is valued slightly cheaper when compared to this.
  • The Price/Forward Earnings ratio is 15.88, which indicates a correct valuation of REGN.
  • 95.92% of the companies in the same industry are more expensive than REGN, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 22.12. REGN is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 16.77
Fwd PE 15.88
REGN Price Earnings VS Forward Price EarningsREGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, REGN is valued cheaply inside the industry as 95.53% of the companies are valued more expensively.
  • REGN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. REGN is cheaper than 95.34% of the companies in the same industry.
Industry RankSector Rank
P/FCF 20.9
EV/EBITDA 11.67
REGN Per share dataREGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150 200 250

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates REGN does not grow enough to justify the current Price/Earnings ratio.
  • REGN has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as REGN's earnings are expected to grow with 12.23% in the coming years.
PEG (NY)2.98
PEG (5Y)2.4
EPS Next 2Y11.49%
EPS Next 3Y12.23%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. REGN Dividend Analysis

5.1 Amount

  • REGN has a yearly dividend return of 0.49%, which is pretty low.
  • Compared to an average industry Dividend Yield of 0.67, REGN pays a better dividend. On top of this REGN pays more dividend than 98.45% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, REGN's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.49%

5.2 History

  • REGN does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
REGN Yearly Dividends per shareREGN Yearly Dividends per shareYearly Dividends per share 2025 2026 1 2 3

5.3 Sustainability

  • 8.22% of the earnings are spent on dividend by REGN. This is a low number and sustainable payout ratio.
DP8.22%
EPS Next 2Y11.49%
EPS Next 3Y12.23%
REGN Yearly Income VS Free CF VS DividendREGN Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B
REGN Dividend Payout.REGN Dividend Payout, showing the Payout Ratio.REGN Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

REGN Fundamentals: All Metrics, Ratios and Statistics

REGENERON PHARMACEUTICALS

NASDAQ:REGN (4/27/2026, 8:14:58 PM)

Premarket: 751 +6.56 (+0.88%)

744.44

-7.13 (-0.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-30
Earnings (Next)04-29
Inst Owners90.76%
Inst Owner Change0.18%
Ins Owners1.94%
Ins Owner Change3.34%
Market Cap78.70B
Revenue(TTM)14.34B
Net Income(TTM)4.50B
Analysts81.58
Price Target880.98 (18.34%)
Short Float %2.79%
Short Ratio4.41
Dividend
Industry RankSector Rank
Dividend Yield 0.49%
Yearly Dividend3.44
Dividend Growth(5Y)N/A
DP8.22%
Div Incr Years0
Div Non Decr Years0
Ex-Date02-20
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.31%
Min EPS beat(2)5.66%
Max EPS beat(2)20.96%
EPS beat(4)3
Avg EPS beat(4)16.93%
Min EPS beat(4)-8.66%
Max EPS beat(4)49.77%
EPS beat(8)6
Avg EPS beat(8)9.59%
EPS beat(12)10
Avg EPS beat(12)8.05%
EPS beat(16)13
Avg EPS beat(16)8.3%
Revenue beat(2)2
Avg Revenue beat(2)1.44%
Min Revenue beat(2)0.21%
Max Revenue beat(2)2.66%
Revenue beat(4)3
Avg Revenue beat(4)0.82%
Min Revenue beat(4)-9.31%
Max Revenue beat(4)9.72%
Revenue beat(8)4
Avg Revenue beat(8)0.06%
Revenue beat(12)8
Avg Revenue beat(12)0.91%
Revenue beat(16)12
Avg Revenue beat(16)1.57%
PT rev (1m)0.76%
PT rev (3m)5.13%
EPS NQ rev (1m)-0.57%
EPS NQ rev (3m)-13.81%
EPS NY rev (1m)0.27%
EPS NY rev (3m)1.44%
Revenue NQ rev (1m)0.85%
Revenue NQ rev (3m)0.48%
Revenue NY rev (1m)0.5%
Revenue NY rev (3m)4.06%
Valuation
Industry RankSector Rank
PE 16.77
Fwd PE 15.88
P/S 5.49
P/FCF 20.9
P/OCF 15.81
P/B 2.52
P/tB 2.62
EV/EBITDA 11.67
EPS(TTM)44.38
EY5.96%
EPS(NY)46.88
Fwd EY6.3%
FCF(TTM)35.61
FCFY4.78%
OCF(TTM)47.1
OCFY6.33%
SpS135.67
BVpS295.66
TBVpS283.76
PEG (NY)2.98
PEG (5Y)2.4
Graham Number543.349 (-27.01%)
Profitability
Industry RankSector Rank
ROA 11.11%
ROE 14.41%
ROCE 10.71%
ROIC 9.6%
ROICexc 29.34%
ROICexgc 32.83%
OM 27.02%
PM (TTM) 31.41%
GM 86.56%
FCFM 26.25%
ROA(3y)11.58%
ROA(5y)16.27%
ROE(3y)14.89%
ROE(5y)21.37%
ROIC(3y)11.3%
ROIC(5y)18.08%
ROICexc(3y)21.75%
ROICexc(5y)28.65%
ROICexgc(3y)23.56%
ROICexgc(5y)30%
ROCE(3y)12.6%
ROCE(5y)20.17%
ROICexgc growth 3Y6.69%
ROICexgc growth 5Y2.24%
ROICexc growth 3Y4.54%
ROICexc growth 5Y-0.03%
OM growth 3Y-14.45%
OM growth 5Y-8.44%
PM growth 3Y-4.13%
PM growth 5Y-5.35%
GM growth 3Y-1.04%
GM growth 5Y-0.06%
F-Score5
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 0.72
Debt/EBITDA 0.61
Cap/Depr 223.23%
Cap/Sales 8.46%
Interest Coverage 93.15
Cash Conversion 112.68%
Profit Quality 83.58%
Current Ratio 4.13
Quick Ratio 3.56
Altman-Z 7.39
F-Score5
WACC9.3%
ROIC/WACC1.03
Cap/Depr(3y)208.61%
Cap/Depr(5y)258.46%
Cap/Sales(3y)7.24%
Cap/Sales(5y)7.69%
Profit Quality(3y)85.52%
Profit Quality(5y)83.15%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.76%
EPS 3Y1.53%
EPS 5Y6.99%
EPS Q2Q%-5.22%
EPS Next Y5.64%
EPS Next 2Y11.49%
EPS Next 3Y12.23%
EPS Next 5Y10.77%
Revenue 1Y (TTM)0.99%
Revenue growth 3Y5.62%
Revenue growth 5Y11.04%
Sales Q2Q%2.51%
Revenue Next Year11.11%
Revenue Next 2Y10.62%
Revenue Next 3Y9.96%
Revenue Next 5Y8.35%
EBIT growth 1Y-8.13%
EBIT growth 3Y-9.64%
EBIT growth 5Y1.67%
EBIT Next Year11.46%
EBIT Next 3Y13.98%
EBIT Next 5Y4.73%
FCF growth 1Y6.39%
FCF growth 3Y3.48%
FCF growth 5Y13.45%
OCF growth 1Y12.63%
OCF growth 3Y-0.24%
OCF growth 5Y13.72%

REGENERON PHARMACEUTICALS / REGN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for REGENERON PHARMACEUTICALS?

ChartMill assigns a fundamental rating of 6 / 10 to REGN.


What is the valuation status of REGENERON PHARMACEUTICALS (REGN) stock?

ChartMill assigns a valuation rating of 6 / 10 to REGENERON PHARMACEUTICALS (REGN). This can be considered as Fairly Valued.


What is the profitability of REGN stock?

REGENERON PHARMACEUTICALS (REGN) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for REGN stock?

The Price/Earnings (PE) ratio for REGENERON PHARMACEUTICALS (REGN) is 16.77 and the Price/Book (PB) ratio is 2.52.


Can you provide the expected EPS growth for REGN stock?

The Earnings per Share (EPS) of REGENERON PHARMACEUTICALS (REGN) is expected to grow by 5.64% in the next year.